Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
$0.32
-0.7%		$0.56
$0.32
▼
$15.75
$2.36M3.69266,302 shs192,782 shs
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$0.02
$0.02
$0.25
▼
$3.56
$708K2.34455,220 shs20 shs
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
$0.82
-10.9%		$1.61
$0.82
▼
$4.59
$2.08M-0.872.50 million shs86,453 shs
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
$2.59
+3.2%		$4.10
$2.05
▼
$78.75
$2.30M1.83.45 million shs237,567 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
0.00%-8.80%-37.24%-73.10%-97.62%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00%0.00%0.00%0.00%-14.29%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
0.00%-24.77%-50.30%-60.58%-66.94%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
0.00%-14.52%-7.50%-79.23%-96.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
$0.32
-0.7%		$0.56
$0.32
▼
$15.75
$2.36M3.69266,302 shs192,782 shs
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$0.02
$0.02
$0.25
▼
$3.56
$708K2.34455,220 shs20 shs
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
$0.82
-10.9%		$1.61
$0.82
▼
$4.59
$2.08M-0.872.50 million shs86,453 shs
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
$2.59
+3.2%		$4.10
$2.05
▼
$78.75
$2.30M1.83.45 million shs237,567 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
0.00%-8.80%-37.24%-73.10%-97.62%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00%0.00%0.00%0.00%-14.29%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
0.00%-24.77%-50.30%-60.58%-66.94%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
0.00%-14.52%-7.50%-79.23%-96.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
2.00
Hold$150.0046,760.36% Upside
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00
N/AN/AN/A
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
1.00
SellN/AN/A
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SQZ, GOVX, VBIO, and TCRT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/15/2026
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
Noble Financial logo
Noble Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/17/2026
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/31/2026
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
$2.49M0.95N/AN/A$2.21 per share0.14
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$18.16M0.04N/AN/A$1.94 per share0.01
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/AN/AN/AN/A$0.93 per shareN/A
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
$780K2.96N/AN/A$166.26 per share0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-$21.47M-$11.34N/AN/AN/AN/A-743.64%-394.74%11/12/2026 (Estimated)
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/A
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
-$4.18M-$1.91N/AN/AN/AN/A-232.60%-158.99%11/17/2026 (Estimated)
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
-$8.88M-$159.25N/AN/AN/AN/A-193.17%-67.10%N/A

Latest SQZ, GOVX, VBIO, and TCRT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/A-$0.41N/A-$0.41N/AN/A
7/27/2026Q2 2026
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-$2.16-$0.97+$1.19-$0.97N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
N/AN/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/AN/A
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/AN/AN/AN/AN/A
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
N/A
1.54
1.54
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/A
3.50
3.50
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/A
0.77
0.77
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
1.74
1.11
0.86

Institutional Ownership

CompanyInstitutional Ownership
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
6.09%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
38.51%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
27.72%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
4.25%

Insider Ownership

CompanyInsider Ownership
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
0.22%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
16.00%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
16.14%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
197.37 million7.35 millionNot Optionable
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
1,62029.49 million24.77 millionNot Optionable
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
12.54 million2.13 millionNo Data
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
10890,000866,000Not Optionable

Recent News About These Companies

Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
September 30, 2026  |  accessnewswire.comA
Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Sees Large Decline in Short Interest
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31055550
Valion Bio, Inc. Announces Appointment of Dean Zikria as Interim Chief Executive Officer
September 25, 2026  |  marketscreener.comM
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
September 23, 2026  |  accessnewswire.comA
Valion Bio, Inc.: Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
September 23, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69644124-valion-bio-inc-valion-bio-regains-compliance-with-nasdaq-minimum-bid-price-listing-rule-200.htm
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
September 22, 2026  |  accessnewswire.comA
VBIO - Valion Bio, Inc.
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/VBIO/historical-price-quotes
Valion Bio Announces Changes to Management and Board of Directors
September 1, 2026  |  accessnewswire.comA
Valion Bio's Reverse Stock Split Takes Effect Today, August 31, 2026; Stock Up
August 31, 2026  |  rttnews.comhttps://www.rttnews.com/3687070/valion-bio-s-reverse-stock-split-takes-effect-today-august-31-2026-stock-up.aspx
Valion Bio, Inc.: Valion Bio Announces Reverse Stock Split
August 27, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69425881-valion-bio-inc-valion-bio-announces-reverse-stock-split-200.htm
Valion Bio Inc VBIO
August 25, 2026  |  morningstar.comM
Valion Bio, Inc. (VBIO)
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VBIO/key-statistics/
Valion Bio Inc.
August 17, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/vbio-valion-bio-inc/vitals
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
August 13, 2026  |  accessnewswire.comA
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury
August 12, 2026  |  accessnewswire.comA
Valion Bio, Inc.
July 22, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/VBIO
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
July 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ukraine-ministry-of-health-accepts-entolimod-dossier-for-formal-review-under-regulatory-equivalence-pathway-302832086.html
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
July 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/world-premier-cancer-center-sheba-medical-center-selects-entolimod-for-clinical-trial-potentially-expanding-valion-bio-into-the-multi-billion-dollar-neutropenia-market-302829829.html
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
July 14, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/valion-bio-advances-integrated-biodefense-and-immunology-platform-through-continued-government-engagement-domestic-manufacturing-and-oncology-expansion-302824523.html
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
June 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/afrriniaid-designs-proprietary-pbi-bm2-5-protocol-to-evaluate-valion-bios-nasdaq-vbio-entolimod-as-the-first-and-only-treatment-for-gi-ars-302810088.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

GeoVax Labs stock logo

GeoVax Labs NASDAQ:GOVX

$0.32 0.00 (-0.65%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$0.31 -0.01 (-1.91%)
As of 10/2/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

SQZ Biotechnologies stock logo

SQZ Biotechnologies NYSE:SQZ

$0.02 0.00 (0.00%)
As of 10/2/2026

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Alaunos Therapeutics stock logo

Alaunos Therapeutics NASDAQ:TCRT

$0.82 -0.10 (-10.87%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$0.86 +0.04 (+5.00%)
As of 10/2/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Valion Bio, Inc. Common Stock stock logo

Valion Bio, Inc. Common Stock NASDAQ:VBIO

$2.59 +0.08 (+3.19%)
As of 10/2/2026 04:00 PM Eastern

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas